Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
By: Marc Oliva, Pierre H H Schneeberger, Victor Rey, Matthew Cho, Rachel Taylor, Aaron R Hansen, Kirsty Taylor, Ali Hosni, Andrew Bayley, Andrew J Hope, Scott V Bratman, Jolie Ringash, Simron Singh, Ilan Weinreb, Bayardo Perez-Ordoñez, Douglas Chepeha, John Waldron, Wei Xu, David Guttman, Lillian L Siu, Bryan Coburn, Anna Spreafico

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
2020-05-31; doi: 10.1038/s41416-020-01253-1
Abstract

Background

Oral and gut microbiomes have emerged as potential biomarkers in cancer. We characterised the oral and gut microbiomes in a prospective observational cohort of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) patients and evaluated the impact of chemoradiotherapy (CRT).

Methods

Saliva, oropharyngeal swabs over the tumour site and stool were collected at baseline and post-CRT. 16S RNA and shotgun metagenomic sequencing were used to generate taxonomic profiles, including relative abundance (RA), bacterial density, α-diversity and β-diversity.

Results

A total of 132 samples from 22 patients were analysed. Baseline saliva and swabs had similar taxonomic composition (R2 = 0.006; p = 0.827). Oropharyngeal swabs and stool taxonomic composition varied significantly by stage, with increased oral RA of Fusobacterium nucleatum observed in stage III disease (p < 0.05). CRT significantly reduced the species richness and increased the RA of gut-associated taxa in oropharyngeal swabs (p < 0.05), while it had no effect in stool samples. These findings remained significant when adjusted by stage, smoking status and antibiotic use.

Conclusions

Baseline oral and gut microbiomes differ by stage in this HPV+ cohort. CRT caused a shift towards a gut-like microbiome composition in oropharyngeal swabs. Stage-specific features and the transitions in oral microbiome might have prognostic and therapeutic implications.





PMID:33750907






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements